{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:04:59Z","timestamp":1791875099633,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["NIH-NIAMS P30AR072577"],"award-info":[{"award-number":["NIH-NIAMS P30AR072577"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1136\/ard-2024-225652","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T17:15:39Z","timestamp":1715793339000},"page":"1368-1374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Gout risk in adults with pre-diabetes initiating metformin"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-4269","authenticated-orcid":false,"given":"Javier","family":"Marrugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8951-2296","authenticated-orcid":false,"given":"Leah M","family":"Santacroce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8361-0650","authenticated-orcid":false,"given":"Misti L","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3082-1374","authenticated-orcid":false,"given":"Sho","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-564X","authenticated-orcid":false,"given":"Alexander","family":"Turchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-1363","authenticated-orcid":false,"given":"Sara K","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8202-5428","authenticated-orcid":false,"given":"Daniel H","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-225652_bib1","author":"Centers for Disease Control and Prevention"},{"key":"10.1136\/ard-2024-225652_bib2","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.2337\/dc23-S003","article-title":"Prevention or delay of type 2 diabetes and associated Comorbidities: standards of care in Diabetes-2023 [published correction appears in Diabetes Care. 2023 Sep 1;46(9):1716-1717]","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1136\/ard-2024-225652_bib3","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1136\/ard.2010.130013","article-title":"Impact of diabetes against the future risk of developing gout","volume":"69","author":"Rodr\u00edguez","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225652_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3199","article-title":"Epidemiology of gout","volume":"12","author":"Roddy","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-225652_bib5","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout [published correction appears in Lancet. 2021 May 15;397(10287):1808]","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225652_bib6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","article-title":"Inflammation in gout: mechanisms and therapeutic targets","volume":"13","author":"So","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-225652_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/annrheumdis-2018-214656","article-title":"mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy","volume":"78","author":"Vazirpanah","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225652_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dom.14559","article-title":"Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"24","author":"Ferreira","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1136\/ard-2024-225652_bib9","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","article-title":"The effects of Canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS program","volume":"1","author":"Li","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-225652_bib10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the risk for gout with sodium\u2013glucose Cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2024-225652_bib11","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/pds.5252","article-title":"Sodium\u2010glucose cotransporter\u20102 inhibitors and the risk of gout: a Danish population based cohort study and symmetry analysis","volume":"30","author":"Lund","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1136\/ard-2024-225652_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.30885","article-title":"Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ard-2024-225652_bib13","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/JOE-21-0194","article-title":"Metformin as an anti-inflammatory agent: a short review","volume":"251","author":"Krist\u00f3fi","year":"2021","journal-title":"J Endocrinol"},{"key":"10.1136\/ard-2024-225652_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/ph13090234","article-title":"Metformin: a potential therapeutic tool for rheumatologists","volume":"13","author":"Salvatore","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1136\/ard-2024-225652_bib15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/1871530315666150316124019","article-title":"Metformin and inflammation: its potential beyond glucose-lowering effect","volume":"15","author":"Saisho","year":"2015","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1136\/ard-2024-225652_bib16","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3389\/fimmu.2018.01236","article-title":"\u201cMetformin and autoimmunity: a \u201cnew deal\u201d of an old drug\u201d","volume":"9","author":"Ursini","year":"2018","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225652_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/20406223231163115","article-title":"Metformin adherence and the risk of cardiovascular disease: a population-based cohort study","volume":"14","author":"Yu","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1136\/ard-2024-225652_bib18","doi-asserted-by":"crossref","first-page":"155160","DOI":"10.1016\/j.metabol.2022.155160","article-title":"Metformin and the heart: update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure","volume":"130","author":"Schernthaner","year":"2022","journal-title":"Metabolism"},{"key":"10.1136\/ard-2024-225652_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/DDDT.S233932","article-title":"Metformin activates the AMPK-mTOR pathway by modulating lncRNA Tug1 to induce autophagy and inhibit atherosclerosis","volume":"14","author":"You","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1136\/ard-2024-225652_bib20","first-page":"854","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet 1998 Nov 7;352(9139):1558]","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225652_bib21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225652_bib22","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14656566.2017.1351945","article-title":"Current and future therapies for gout","volume":"18","author":"Pascart","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1136\/ard-2024-225652_bib23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3122\/jabfm.2022.04.210485","article-title":"Metformin prescription rates for patients with prediabetes","volume":"35","author":"Hughes","year":"2022","journal-title":"J Am Board Fam Med"},{"key":"10.1136\/ard-2024-225652_bib24","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/M14-1773","article-title":"Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study","volume":"162","author":"Moin","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2024-225652_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","article-title":"Estimating causal effects from large data SETS using propensity scores","volume":"127","author":"Rubin","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2024-225652_bib26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies","volume":"21 Suppl 2","author":"Rassen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1136\/ard-2024-225652_bib27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1136\/ard-2024-225652_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1742-7843.2006.pto_293.x","article-title":"Indications for propensity scores and review of their use in pharmacoepidemiology","volume":"98","author":"Glynn","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1136\/ard-2024-225652_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40801-022-00343-1","article-title":"\u201cImpact of \u201ctime zero\u201d of follow-up settings in a comparative effectiveness study using real-world data with a non-user comparator: comparison of six different settings\u201d","volume":"10","author":"Wakabayashi","year":"2023","journal-title":"Drugs - Real World Outcomes"},{"key":"10.1136\/ard-2024-225652_bib30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1136\/ard-2024-225652_bib31","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med. 2011 Sep 20;155(6):408]","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2024-225652_bib32","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1136\/ard-2024-225652_bib33","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1136\/ard-2024-225652_bib34","first-page":"30","article-title":"Multiple imputation with multivariate imputation by chained equation (MICE) package","volume":"4","author":"Zhang","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1136\/ard-2024-225652_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1136\/ard-2024-225652_bib36","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1093\/jamia\/ocv130","article-title":"Combining billing codes, clinical notes, and medications from electronic health records provides superior phenotyping performance","volume":"23","author":"Wei","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"10.1136\/ard-2024-225652_bib37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12891-015-0614-2","article-title":"Validity of gout diagnosis in Swedish primary and secondary care - a validation study","volume":"16","author":"Dehlin","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1136\/ard-2024-225652_bib38","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pds.4044","article-title":"Validation of claims-based algorithms for gout flares","volume":"25","author":"MacFarlane","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1136\/ard-2024-225652_bib39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1136\/ard-2024-225652_bib40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/aje\/kwq439","article-title":"Doubly robust estimation of causal effects","volume":"173","author":"Funk","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1136\/ard-2024-225652_bib41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2024-225652_bib42","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Statistic Associa"},{"key":"10.1136\/ard-2024-225652_bib43","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1536867X1201200209","article-title":"Using the margins command to estimate and interpret adjusted predictions and marginal effects","volume":"12","author":"Williams","year":"2012","journal-title":"Stata J"},{"key":"10.1136\/ard-2024-225652_bib44","doi-asserted-by":"crossref","first-page":"955806","DOI":"10.3389\/fimmu.2022.955806","article-title":"Recent insights into the role of macrophages in acute gout","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225652_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.mce.2017.09.025","article-title":"Metformin improves obesity-associated inflammation by altering macrophages polarization","volume":"461","author":"Jing","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1136\/ard-2024-225652_bib46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.2279","article-title":"The Nlrp3 inflammasome Instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat Med"},{"key":"10.1136\/ard-2024-225652_bib47","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225652_bib48","unstructured":"Medications containing Semaglutide marketed for type 2 diabetes or weight loss. Food and Drug Administration website, Available: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss [Accessed 10 Jan 2024]."},{"key":"10.1136\/ard-2024-225652_bib49","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1136\/bmj.p2506","article-title":"UK regulator WARNS public after seizing hundreds of fake ozempic pens","volume":"383","author":"Mahase","year":"2023","journal-title":"BMJ"},{"key":"10.1136\/ard-2024-225652_bib50","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-225652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T14:24:06Z","timestamp":1736173446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724665192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0003496724665192"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-225652","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gout risk in adults with pre-diabetes initiating metformin","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-225652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}